NEW YORK(GenomeWeb) – Melanoma test development firm DermTech has raised $2.4 million.
DermTech disclosed the financing in a document filed with the US Securities and Exchange Commission earlier this week. In an email, DermTech CFO and Treasurer Steven Kemper told GenomeWeb that participants in the private financing round included existing investors. He added that the La Jolla, Calif.-based firm is launching its pigmented lesion assay and is currently testing the assay with certain US dermatologists with plans for a broader launch in the second half of this year.
DermTech filed with the SEC to go public last spring but shelved those plans in November. The firm develops gene expression tests for diagnosing skin conditions, including skin cancer, inflammatory diseases, and age-related conditions. Its technology uses an "adhesive patch biopsy" that provides a tissue sample non-invasively.